Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

A Randomized, Open-Label, Six-Sequence, Three-Period Crossover Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER Plus CSG452 in Healthy Adult Volunteers, and to Characterize the Food Effect on the Pharmacokinetics of K-001

The goal of this clinical trial is to demonstrate the bioequivalence of single oral administration of K-001 relative to single oral co-administration of separate tablets of K-877-ER and CSG452 in healthy adult volunteers, and to characterize the food effect on the Pharmacokinetics(PK) of K-001.

Inclusion Criteria:

• Participant provides written informed consent before any study-specific evaluation is performed.
• Participant is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive, at Screening.
• Participant has a body mass index of 18 to 30 kg/m2, inclusive, at Screening.
• Participant meet all other inclusion criteria outlined in the clinical study protocol.

Exclusion Criteria:

• Participant has clinically significant abnormalities at Screening or at Check-in assessments, in the opinion of the investigator.
• Participant is pregnant or breastfeeding or intends to become pregnant within 30 days after the last dose of study drug.
• Participant meets any other exclusion criteria outlined in the clinical study protocol.